Table 2.
Treatment and pathologic characteristics
| Treatment characteristics | No. (%) |
|---|---|
| Neoadjuvant chemotherapy | |
| Anthracycline and taxane-based | 124 (97.6) |
| Taxane-based only | 1 (0.8) |
| Other | 2 (1.6) |
| CEA pre-treatment/after surgery ratio | |
| ≥ 0.66 | 96 (75.6) |
| < 0.66 | 31 (24.4) |
| CA 15.3 pre-treatment/after surgery ratio | |
| ≥ 0.8 | 114 (89.8) |
| < 0.8 | 13 (10.2) |
| Neoadjuvant radiotherapy | 16 (12.6) |
| Type of breast surgery | |
| Radical mastectomy | 121 (95.3) |
| Breast conserving surgery | 6 (4.7) |
| Adjuvant radiotherapy | 76 (59.8) |
| Adjuvant chemotherapy | 10 (7.9) |
| Pathologic characteristics | |
| Cellularity | |
| 0–5% | 58 (45.6) |
| 10–50% | 33 (26) |
| > 50% | 5 (4) |
| Unknown | 31 (24.4) |
| Lymph nodes removed in surgery | |
| < 10 | 13 (15.3) |
| ≥ 10 | 72 (84.7) |
| Pathology tumor stage [pT] | |
| < pT3 | 121 (95.3) |
| ≥ pT3 | 6 (4.7) |
| Pathology nodal stage [pN] | |
| pN0 | 100 (79) |
| pN+ | 27 (21) |
| pCR | 62 (48.8) |
| Lymphovascular invasion | 19 (15) |
| Lymphatic emboli | 9 (7.1) |
| Deep margin involvement | 5 (3.9) |
| Calcification | 2 (1.6) |
no — number; pCR — pathologic complete response